In a phase 3 trial exploratory unplanned subgroup analysis of patients with the KIT exon 11 and 17/18 mutation or KIT ALposABPneg (based on circulating tumor DNA), ripretinib demonstrated an RR of 40% and median PFS of 14.2 months, while the median PFS for all patients with a primary KIT exon 11 mutation was 8.3 months in the second-line setting [27]. The gene discussed is KIT; the disease is neoplasm.